NeurogesX Files for $69 Million IPO

NeurogesX Inc., a San Carlos, Calif.-based developer of pain management therapies, has filed for a $69 million IPO. It plans to trade on the Nasdaq under ticker symbol NGSX, with Morgan Stanley serving as lead underwriter. The company has raised around $95 million in total VC funding since its 1998 inception, from firms like Arch Venture Partners (24.7% pre-IPO stake), Alta Partners (18.6%), Walden International (14.3%), Montreaux Equity Partners (10.2%) and Global Lifescience Ventures (6.5%). www.neurogesx.com